Sanofi-Aventis sponsored two major clinical trials to investigate Taxotere in breast cancer patients. The studies found that 3-9% of women who received Taxotere in combination with other chemotherapy drugs experienced persistent hair loss.
The studies investigated Taxotere in combination with Adriamycin (doxorubicin) and cyclophosphamide, a regimen known as TAC chemotherapy.
The outcomes were compared to patients who received chemotherapy that did not include Taxotere — a regimen known as FAC chemotherapy that combines cyclophosphamide, Adriamycin (doxorubicin), and fluorouracil.
Clinical trials linking Taxotere and permanent hair loss:
- TAX316 compared outcomes for 744 women given TAC and 736 women given FAC for breast cancer. Hair loss occurred in 3.9% of women on TAC vs. 2.2% of women on FAC during the 8-year follow-up period.
- GEICAM 9805 compared outcomes for 1,060 women who were randomly assigned to receive TAC or FAC. The study began in the 1990s and at the 10-year follow-up in 2005, 9.2% of women on TAC had persistent hair loss vs. 6.7% on FAC.
Clinical trials have also found that scalp-cooling can prevent some hair loss from chemotherapy with Taxotere. Researchers found that women who wore “cool caps” experienced less hair loss. The caps constrict blood vessels in the scalp, which reduces the amount of chemotherapy drugs that reach hair follicles during treatment.
Do I have a Taxotere Lawsuit?
The Schmidt Firm, PLLC is currently accepting Taxotere induced injury cases in all 50 states. If you or somebody you know has been diagnosed with permanent hair loss, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.